Ex vivo bite-activated T cells

• Main Authors: BALLESTEROS NOBELL JUAN ANTONIO, HERNANDEZ CAMPO PILAR, ROBLES MATEOS ALICIA, PRIMO RAMOS DANIEL, GOMEZ GONZALEZ CRISTINA, GORROCHATEGUI GUILLEN JULIAN, MARTINEZ LOPEZ JOAQUIN, BENNET TERESA ANN
• Format: Patent
• Language: Chinese; English
• Published: 21.05.2019
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

Generation and identification of highly effective immune effector cell in terms of target cell-killing activity can be enhanced by optimizing the proximity between a target cell and the immune effector cell. The cancer-killing T cells described herein can provide highly effective therapies for diverse cancer types, e.g., solid cancers, hematological cancers, and metastatic forms thereof. Providedherein are ex-vivo methods of generating cancer-killing T cells, compositions comprising such immune cells; methods of using the cells, methods of selecting optimal agents for enhancing the target cell killing activity, methods of selecting an optimized immune cell and methods of using this approach to evaluate patient responsiveness to other cancer therapies. 通过优化靶细胞和免疫效应细胞之间的接近度，在靶细胞杀伤活性方面可以增强高效免疫效应细胞的产生和鉴定。本文所述的癌症杀伤T细胞可以为多种癌症类型例如实体癌症，血液癌症及其转移形式提供高效治疗。本文提供了产生癌症杀伤T细胞的离体方法，包含此种免疫细胞的组合物；使用所述细胞的方法，选择用于增强靶细胞杀伤活性的最佳试剂的方法，选择优化的免疫细胞的方法和使用该方法评估患者对其他癌症治疗的应答性的方法。